Perspective Therapeutics, Inc.
CATX
$3.90
-$0.03-0.76%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -81.62% | -43.36% | -44.87% | 5.23% | -30.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -81.62% | -43.36% | -44.87% | 5.23% | -30.56% |
| Cost of Revenue | 155.56% | 69.10% | 79.19% | 86.88% | 110.78% |
| Gross Profit | -159.95% | -72.66% | -86.65% | -90.75% | -119.03% |
| SG&A Expenses | -15.70% | 10.84% | 39.81% | 33.41% | 66.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.72% | 47.71% | 64.51% | 66.35% | 75.56% |
| Operating Income | -90.63% | -49.52% | -68.54% | -67.87% | -78.62% |
| Income Before Tax | 9.42% | -71.73% | -96.17% | -53.72% | -263.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.67% | -71.73% | -96.17% | -53.72% | -106.08% |
| Earnings from Discontinued Operations | -- | -- | 204.90% | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.67% | -71.73% | -83.57% | -47.97% | -62.79% |
| EBIT | -90.63% | -49.52% | -68.54% | -67.87% | -78.62% |
| EBITDA | -92.28% | -50.77% | -70.23% | -66.81% | -76.25% |
| EPS Basic | 16.34% | -63.24% | -64.81% | -1.25% | 31.38% |
| Normalized Basic EPS | -96.76% | -63.30% | -76.05% | -5.16% | 36.98% |
| EPS Diluted | 16.34% | -63.24% | -64.81% | -1.25% | 31.38% |
| Normalized Diluted EPS | -96.76% | -63.30% | -76.05% | -5.16% | 36.98% |
| Average Basic Shares Outstanding | 15.39% | 5.19% | 11.38% | 46.15% | 129.38% |
| Average Diluted Shares Outstanding | 15.39% | 5.19% | 11.38% | 46.15% | 129.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |